This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zhang, Y.-A. Articles by Tong, A. W. Search for Related Content PubMed PubMed Citation Articles by Zhang, Y.-A. Articles by Tong, A. W.

Antitumor Activity of an Oncolytic Adenovirus-Delivered Oncogene Small Interfering RNA

¹ The Mary Crowley Medical Research Center and the ² Cancer Immunology Research Laboratory, Baylor-Sammons Cancer Center, ³ Murex Pharmaceuticals, Dallas, Texas; and ⁴ Institute of Biomedical Studies, Baylor University, Waco, Texas

Requests for reprints: Alex W. Tong, Cancer Immunology Research Laboratory, Baylor Sammons Cancer Center, 530 Sammons Tower, 3500 Gaston Avenue, Dallas, TX 75246. Phone: 214-820-4123; Fax: 214-820-2780; E-mail: alext{at}baylorhealth.edu.

Despite successes in animal models, cancer gene therapy with small interfering RNAs (siRNA) is hindered by the lack of an optimal delivery platform. We examined the applicability of the replication-competent, oncolytic adenovirus, ONYX-411, to deliver a mutant K-ras siRNA transgene to human cancer cells. Proof-of-principle studies showed an additive tumor growth–inhibitory response through siRNA-mediated K-ras knockdown and ONYX-411-mediated cancer cell lysis. A novel construct, termed Internavec (for interfering RNA vector), was generated by cloning a K-ras^v12-specific siRNA^ras-4 hairpin construct under the control of the human H1 promoter into the deleted E3b region of ONYX-411. Internavec acquired an increase in potency of 10-fold in human cancer cells expressing the relevant K-ras^v12 mutation (H79, H441, and SW480), as defined by a reduction in the effective dose needed to achieve 50% growth inhibition (ED₅₀). Internavec remained attenuated in nonmalignant epithelial cells. Daily intratumoral injections of Internavec (five daily injections of 1 x 10⁸ plaque-forming units) significantly reduced the growth of s.c. H79 pancreatic cancer xenografts in nu/nu mice by 85.5%, including complete growth suppression in three of five mice. Parental ONYX-411 or ONYX-411-siRNA^GFP was markedly less effective (47.8% growth reduction, P = 0.03; and 44.1% growth reduction, P = 0.03, respectively). siRNA^ras transgene activity contributed to cell cycle blockage, increased apoptosis, and marked down-regulation of Ras signaling–related gene expression (AKT2, GSK3ß, E2F2, and MAP4K5). These findings indicate that Internavec can generate a two-pronged attack on tumor cells through oncogene knockdown and viral oncolysis, resulting in a significantly enhanced antitumor outcome. (Cancer Res 2006; 66(19): 9736-43)

This article has been cited by other articles:

				E. Gurlevik, N. Woller, P. Schache, N. P. Malek, T. C. Wirth, L. Zender, M. P. Manns, S. Kubicka, and F. Kuhnel p53-dependent antiviral RNA-interference facilitates tumor-selective viral replication Nucleic Acids Res., July 1, 2009; 37(12): e84 - e84. [Abstract] [Full Text] [PDF]

				E. Ramakrishna, N. Woller, B. Mundt, S. Knocke, E. Gurlevik, M. Saborowski, N. Malek, M. P. Manns, T. Wirth, F. Kuhnel, et al. Antitumoral Immune Response by Recruitment and Expansion of Dendritic Cells in Tumors Infected with Telomerase-Dependent Oncolytic Viruses Cancer Res., February 15, 2009; 69(4): 1448 - 1458. [Abstract] [Full Text] [PDF]

				E. M. Gomes, M. S. Rodrigues, A. P. Phadke, L. D. Butcher, C. Starling, S. Chen, D. Chang, R. Hernandez-Alcoceba, J. T. Newman, M. J. Stone, et al. Antitumor Activity of an Oncolytic Adenoviral-CD40 Ligand (CD154) Transgene Construct in Human Breast Cancer Cells Clin. Cancer Res., February 15, 2009; 15(4): 1317 - 1325. [Abstract] [Full Text] [PDF]

				T. John, O. L. Caballero, S. J. Svobodova, A. Kong, R. Chua, J. Browning, S. Fortunato, S. Deb, M. Hsu, C. A. Gedye, et al. ECSA/DPPA2 is an Embryo-Cancer Antigen that Is Coexpressed with Cancer-Testis Antigens in Non-Small Cell Lung Cancer Clin. Cancer Res., June 1, 2008; 14(11): 3291 - 3298. [Abstract] [Full Text] [PDF]